Pharmaceutical News

RSS

Simple treatment may counteract widespread problem of subnormal vitamin levels in acute-care patients

Treatment with vitamin C rapidly improves the emotional state of acutely hospitalized patients, according to a study carried out by researchers at Montreal's Jewish General Hospital (JGH) and the affiliated Lady Davis Institute for Medical Research (LDI).

24 Sep 2010

FDA designates AMT-080 gene therapy for Duchenne muscular dystrophy

Amsterdam Molecular Therapeutics (AMT) Holding N.V. a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug.

24 Sep 2010

ASTMH recommends FDA to include neglected infections of poverty in orphan classification

Today, U.S. scientists committed to finding answers to reducing and eliminating what are known as neglected tropical diseases (NTDs) that plague the world's poorest people in developing countries, urged the FDA to include in its orphan classification the neglected infections of poverty that also affect Americans, and expressed support for stronger relationships with the FDA to ultimately halt these ancient scourges.

24 Sep 2010

FDA grants clearance for HPβCD treatment for Niemann Pick Type C disease

Children's Hospital & Research Center Oakland announced today that the US Food and Drug Administration (FDA) has granted clearance of an Investigational New Drug (IND) application to introduce Trappsol Cyclo (Hydroxypropyl Beta Cyclodextrin or HPβCD) into the brains of six year old identical twin girls dying of a rare brain-destroying cholesterol disease called Niemann Pick Type C (NPC).

24 Sep 2010

Advitech completes UVA testing study on oleosome sunscreen formulation

Advitech Inc. is pleased to announce today that a key UVA testing study has been completed on its oleosome-based sunscreen prototype formulation.

24 Sep 2010

Advanced Targeting Systems receives NCI award to advance SP-SAP drug

Advanced Targeting Systems, the company that pioneered the targeting of specific cell types to manipulate them for the treatment of diseases and for research into the function of biological systems, has been awarded $3 million from the National Cancer Institute (NCI).

24 Sep 2010

Avandia restricted by the FDA and EMEA

The U.S. Food and Drugs Administration (FDA) has restricted the use of the controversial diabetes drug Avandia (rosiglitazone) due to its propensity to increase cardiovascular disease risk.

24 Sep 2010

FDA approves Bionovo's CMC plan for Menerba drug candidate

Bionovo, Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted the Company's Chemistry, Manufacturing and Controls (CMC) plan for its lead drug candidate, Menerba, in a Type "B" or "End of Phase 2" meeting.

24 Sep 2010

Abbott, Reata enter agreement to commercialize bardoxolone drug for CKD

Abbott and Reata Pharmaceuticals today announced that they have entered into a collaboration agreement to develop and commercialize bardoxolone methyl (bardoxolone), which is currently in late Phase 2 trials for the treatment of chronic kidney disease (CKD).

24 Sep 2010

Cardialysis and Sticares InterACT announce strategic collaboration

Cardialysis and Sticares InterACT, both Contract Research Organizations (CROs) headquartered in The Netherlands, announced today that they have entered into a strategic collaboration to provide drug development consulting services in the field of cardiovascular and metabolic medicine. Both organizations have substantial experience and success in the execution of clinical research projects for pharmaceutical, biotechnology and medical device companies.

23 Sep 2010

ENTrigue partners with HemCon to distribute hemostatic surgical gel

HemCon Medical Technologies, a global innovative developer of advanced medical technologies and products, has recently partnered with ENTrigue Surgical, Inc., a leading provider of medical devices and therapies for surgeries of the Ear, Nose and Throat, to develop and distribute HemCon's latest breakthrough product, a hemostatic surgical gel.

23 Sep 2010

Raltegravir could be valid target against all Herpesviridae

Scientists at the Institute for Research in Biomedicine (IRB Barcelona) headed by the coordinator of the Structural and Computational Biology Programme, Miquel Coll, have published a new study that demonstrates that raltegravir, the drug approved in 2007 for the treatment of AIDS that is sold by Merck under the name Isentress, cancels the function of an essential protein for the replication of one kind of herpes virus.

23 Sep 2010

Athersys presents MultiStem phase I study results at TCT Conference

Athersys, Inc. announced at its presentation at the Transvascular Cardiovascular Therapeutics (TCT) Conference held in Washington, D.C., updated results from its phase I clinical trial of MultiStem, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI).

23 Sep 2010

Semprae Laboratories markets Zestra to help make sex effortless for women

Last night's ABC NIGHTLINE segment questioned why culture and advertisers remain so reluctant to give women what they want. Meanwhile, for men, it's been common practice to discuss their sexual needs openly.

23 Sep 2010

LSUHSC hosts international scientific conference on drug abuse research and politics

Topics ranging from the future of addiction research and treatment to the binational implications of Mexico's decriminalization of drugs will be presented at the 10th Annual International Conference of the National Hispanic Science Network (NHSN) on Drug Abuse September 30 - October 2, 2010 at The Westin New Orleans Canal Place.

23 Sep 2010

Scientists to develop methotrexate nose drops for brain cancer

Scientists are reporting the development and successful initial testing of a new form of methotrexate the mainstay anticancer drug designed to be given as nose drops rather than injected. It shows promise as a more effective treatment for brain cancer, they say. The report appears in ACS' Molecular Pharmaceutics, a bi-monthly journal.

23 Sep 2010

FDA and EMA accept regulatory submissions of vandetanib for advanced medullary thyroid cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted regulatory submissions for review of the investigational drug vandetanib in the treatment of patients with advanced medullary thyroid cancer (MTC). The FDA also granted priority review status for the new drug application and set a Prescription Drug User Fee Act (PDUFA) action date of 7 January 2011.

23 Sep 2010

New analytical technique to improve personalized medicine

In the future, even before the start of the treatment, physicians will be able to establish how patient's blood binds a given medicine and what doze should be applied in order to obtain the concentration in the body that would be optimal for the treatment. A new simple method of analysis of chemical reactions proceeding in solutions has been developed in the Institute of Physical Chemistry of the Polish Academy of Sciences.

23 Sep 2010

RXi, EyeGate collaborate to develop RNAi therapeutics for retinal disorders

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutics, and EyeGate Pharma, the leader in non-invasive ocular drug delivery announced today that they will collaborate on the ocular delivery of RNAi therapeutics. Each party will contribute technology, expertise, and resources to the collaboration.

23 Sep 2010